BioCentury | Apr 3, 2014
Cover Story

Critical mass in diabetes

...of Evotec AG . Evotec and the MedImmune LLC unit of AstraZeneca plc are developing EVT 770...
BioCentury | Oct 28, 2013
Strategy

Playing in the gap

...rights to preclinical diabetes compounds that promote regeneration of insulin-producing beta cells. That collaboration yielded EVT 770...
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

...AZ has three in-licensed diabetes programs: PSN821 and PSN842 from Astellas Pharma Inc. , and EVT 770...
...The Astellas programs target GPR119 and are in Phase II and preclinical development, respectively. EVT 770...
...B) AstraZeneca plc (LSE:AZN; NYSE:AZN) PSN821 [Astellas Pharma Inc. (Tokyo:4503)] (A) GPR119 agonist Ph II EVT 770...
BioCentury | Apr 19, 2012
Targets & Mechanisms

Blocking p75 NTR in diabetes

...proof of concept in animal models," Dohrmann told SciBX . Evotec's b cell regeneration factor, EVT 770...
Items per page:
1 - 4 of 4